Literature DB >> 7622422

Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.

E Miyagi1, H Yasumitsu, F Hirahara, H Minaguchi, N Koshikawa, K Miyazaki, M Umeda.   

Abstract

Matrix-degrading proteinases secreted by tumor cells play crucial roles in tumor cell invasion and metastasis. Serum-free conditioned media of 7 human gynecological carcinoma cell lines were examined for proteinases and their inhibitors by using gelatin zymography, reverse zymography and immunoblotting. All of three ovarian adenocarcinoma cell lines secreted urokinase-type plasminogen activator. Among them, a mucinous cystadenocarcinoma cell line also secreted tissue-type plasminogen activator, plasmin-like enzyme and trypsinogen. On the other hand, two ovarian undifferentiated carcinoma cell lines mainly secreted glatinase A or B. A choriocarcinoma cell line secreted multiple metalloproteinases in the highest amount, whereas an endometrial adenocarcinoma cell line (HEC-1) derived from an early clinical stage hardly secreted any gelatinolytic enzyme. The five high proteinases producers hardly secreted the corresponding inhibitors, such as tissue inhibitor of metalloproteinases (TIMP)-1, -2 or plasminogen activator inhibitor-1. In contrast to these highly malignant cell lines, a poor proteinase producer, HEC-1, secreted a large amount of TIMPs. Therefore, an enhanced proteolytic tendency appears to be associated with gynecological cancer cells established from highly malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7622422      PMCID: PMC5920870          DOI: 10.1111/j.1349-7006.1995.tb02436.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  35 in total

1.  Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases.

Authors:  A R Mackay; R H Corbitt; J L Hartzler; U P Thorgeirsson
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells.

Authors:  Y A De Clerck; T D Yean; B J Ratzkin; H S Lu; K E Langley
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

3.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

4.  Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells.

Authors:  Y E Shi; J Torri; L Yieh; A Wellstein; M E Lippman; R B Dickson
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

5.  Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix.

Authors:  E Koivunen; A Ristimäki; O Itkonen; S Osman; M Vuento; U H Stenman
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

6.  Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase.

Authors:  E Koivunen; M L Huhtala; U H Stenman
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

7.  Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; R J Muschel; E N Hughes
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2.

Authors:  G I Goldberg; B L Marmer; G A Grant; A Z Eisen; S Wilhelm; C S He
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.

Authors:  E J Bernhard; S B Gruber; R J Muschel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  Malignant cell-specific gelatinase activity in human endometrial carcinoma.

Authors:  M Takemura; C Azuma; T Kimura; Y Tokugawa; M Miki; M Ono; F Saji; O Tanizawa
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

View more
  5 in total

1.  Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells.

Authors:  S Miyata; Y Miyagi; N Koshikawa; Y Nagashima; Y Kato; H Yasumitsu; F Hirahara; K Misugi; K Miyazaki
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

2.  MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes.

Authors:  Mohit Sachdeva; Jeffrey K Mito; Chang-Lung Lee; Minsi Zhang; Zhizhong Li; Rebecca D Dodd; David Cason; Lixia Luo; Yan Ma; David Van Mater; Rebecca Gladdy; Dina C Lev; Diana M Cardona; David G Kirsch
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

3.  Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer.

Authors:  Y E Joo; K S Seo; H S Kim; J S Rew; C S Park; S J Kim
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

4.  An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma.

Authors:  T Miyazaki; H Kato; M Nakajima; A Faried; J Takita; M Sohda; Y Fukai; S Yamaguchi; N Masuda; R Manda; M Fukuchi; H Ojima; K Tsukada; H Kuwano
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

5.  Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma.

Authors:  K Mimori; M Mori; T Shiraishi; T Fujie; K Baba; M Haraguchi; R Abe; H Ueo; T Akiyoshi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.